{"url_path":"/sec/celuw/8-k/2026-06-03/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1752828/0001493152-26-027132-index.html","accession_number":"0001493152-26-027132","cik":"0001752828","ticker":"CELU","issuer_name":"Celularity Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1752828/0001493152-26-027132-index.html","primary_entity_key":"0001752828","primary_entity_name":"Celularity Inc"},"word_count":209,"has_tables":true,"body_markdown":"** **\n\n**Item\n7.01. Regulation FD Disclosure.**\n\n** **\n\nOn\nJune 3, 2026, Celularity issued a press release announcing the appointment of Mr. Gonzalez as Chief Commercial Officer. A copy of the\npress release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\nAlso\non June 3, 2026, Celularity made available a letter to shareholders from Dr. Hariri, providing an update on Celularity’s strategic\nfocus, including its focus on longevity, regenerative medicine and the preservation of human performance, its commercial opportunity\nfor cenplacel-L, its Lifebank cellular banking platform, and the appointment of Mr. Gonzalez as Chief Commercial Officer. A copy of the\nshareholder letter is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\nThe\ninformation in this Item 7.01, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for purposes\nof Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall\nnot be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act\nof 1934, as amended, except as expressly set forth by specific reference in such filing."}